Sleep Apnea Prevalent Among Cardio-Oncology Patients
By Elana Gotkine HealthDay Reporter
MONDAY, Feb. 12, 2024 -- Sleep apnea is prevalent among 35 percent of cardio-oncology patients, and those with untreated sleep apnea have significantly abnormal Global Longitudinal Left Ventricular (LV) Strain (GLS), according to a study presented at the Advancing the Cardiovascular Care of the Oncology Patient conference organized by the American College of Cardiology and held from Feb. 9 to 11 in Washington, D.C.
Mini K. Das, M.D., from Baptism Health in Louisville, Kentucky, and colleagues collected data from 296 general cardiology patients and 240 cardio-oncology patients to examine the prevalence and impact of sleep apnea.
The researchers found that the prevalence of sleep apnea was 54 percent in general cardiology patients and 35 percent among the cardio-oncology patients. In the cardio-oncology patients, sleep apnea prevalence was higher than several traditional risk factors used in cardiovascular risk stratification for cardiotoxicity. LV ejection fraction was relatively similar for patients with treated or untreated sleep apnea and for those with high scores on the Snoring, Tiredness, Observed apnea, elevated blood Pressure, Body mass index, Age, Neck, Gender (STOP-BANG) screening tool. Patients with untreated sleep apnea and patients with high STOP-BANG scores had significantly abnormal GLS.
"Sleep apnea should be incorporated into current risk algorithms and a larger study is needed to evaluate the impact of sleep apnea in this high-risk population," Das said in a statement. "We feel that sleep apnea assessment must be a part of routine risk assessment for patients undergoing cancer therapeutics."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
ASCO: Germline Variation Does Not Predict Taxane-Induced Peripheral Neuropathy
FRIDAY, June 7, 2024 -- Germline variation does not predict the risk of taxane-induced peripheral neuropathy (TIPN) in Black women receiving paclitaxel (once weekly) or docetaxel...
Prevalence of Cardiovascular Risk Factors, Diseases Set to Increase
THURSDAY, June 6, 2024 -- The prevalence of cardiovascular risk factors and diseases will increase through 2050, and the associated economic burden is also projected to increase...
Adherence to Mediterranean Diet Linked to Lower Risk for Mortality
TUESDAY, June 4, 2024 -- Adherence to the Mediterranean diet is associated with a lower risk for all-cause mortality, which is partly explained by multiple cardiometabolic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.